Vanda Pharmaceuticals Inc. operates in the Pharmaceutical preparations sector. Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. The Company's products include Fanapt and Tasimelteon. Fanapt (iloperidone) is a compound for the treatment of schizophrenia. On October 12, 2009, Vanda entered into an amended and restated sublicense agreement with Novartis. On January 11, 2010, Novartis launched Fanapt in the United States. Tasimelteon is a compound for the treatment of sleep and mood disorders, including Circadian Rhythm Sleep Disorders (CRSD). On January 19, 2010, the United States Food and Drug Administration (FDA) granted orphan drug designation status for tasimelteon in a specific CRSD, non-24-hour sleep/wake disorder (N24HSWD) in blind individuals without light perception. In our complete report available for purchase the company is compared to: Allos Therapeutics, Inc., Xenoport, Inc. and Dusa Pharmaceuticals, Inc..